Ibafloxacin |
![]() Last updated: 15/09/2025 |
![]() |
(Also known as: ibafloxacinum; ibafloxacine; ibaflin) |
|
![]() |
|
A broad spectrum veterinary antibiotic with bactericidal action against gram-positive and gram-negative bacteria. | |
---|---|---|
|
Used for skin diseases such as canine pyoderma | |
|
Dogs; Cats |
Approval status |
|
Not approved | |
---|---|---|
|
Not approved |
Chemical structure |
|
Ibafloxacin exhibits optical isomerism due to the presence of chiral centres in its molecular structure. Specifically, it contains at least one stereocentre on its fused tricyclic ring system, which allows for the existence of enantiomers. Ibafloxacin is typically administered as a single, stereochemically defined isomer, chosen for its optimal antibacterial efficacy and safety profile. | |
---|---|---|
|
C₁₅H₁₄FNO₃ | |
|
CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2C)F)C(=O)O | |
|
No data | |
|
DXKRGNXUIRKXNR-UHFFFAOYSA-N | |
|
InChI=1S/C15H14FNO3/c1-7-3-4-9-8(2)12(16)5-10-13(9)17(7)6-11(14(10)18)15(19)20/h5-7H,3-4H2,1-2H3,(H,19,20) | |
|
Yes |
General status |
|
Antibiotic, Antibacterial | |
---|---|---|
|
Quinolone | |
|
- | |
|
- | |
|
Synthetic | |
|
Inhibits the enzyme DNA-gyrase, an essential enzyme which maintains superhelical twists in bacterial DNA molecules | |
|
[DNA gyrase subunit A, Antagonist] | |
|
91618-36-9 | |
|
- | |
|
- | |
|
- | |
|
- | |
|
Antiinfectants for systemic use: Antibacterials for systemic use | |
|
QJ01MA96 | |
|
No | |
|
- | |
|
275.27 | |
|
- | |
|
6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo(i,j)quinolizine-2-carboxylic acid | |
|
- | |
|
- | |
|
- | |
|
- | |
|
Dirty white coloured solid |
Commercial |
|
|
|||
---|---|---|---|---|
|
- | |||
|
1990s, initial registeration Europe; Early 2000s, start of withdrawal | |||
|
|
|||
|
|
|||
|
Usually supplied in formulations for oral administration including oral gels and tablets | |||
|
Ibafloxacin is synthesised through a multi-step chemical process typical of fluoroquinolone antibiotics, beginning with the construction of its core quinolone ring system. This involves condensation reactions between substituted anilines and carboxylic acid derivatives, followed by cyclisation to form the fused tricyclic structure. A key step includes the introduction of a fluorine atom at the C-6 position, which enhances antibacterial potency and cell penetration. The molecule also incorporates a piperazine or similar nitrogen-containing ring at the C-7 position to improve pharmacokinetics and spectrum of activity. Throughout the synthesis, stereochemical control is essential to ensure the correct configuration at the chiral centre, as only one enantiomer exhibits optimal therapeutic effects. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
269 | L3 L = Pesticide manuals and hard copy reference books / other sources 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
> 2000 | Q3 Q = Miscellaneous data from online sources Rat3 = Unverified data of known source |
Low | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
High (class III) | - | - | ||||||||
|
> 2000 | Q3 Q = Miscellaneous data from online sources Rat3 = Unverified data of known source |
Low | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
The main excretion routes are the urine and faeces | A5 A = EU regulatory and evaluation data as published by EC, EFSA (RAR, DAR & Conclusion dossiers), EMA (e.g. EU Annex III PIC DGD) (EU - Pesticides database; EFSA Scientific Publications ) 5 = Verified data used for regulatory purposes |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
No further informatoion available |
Handling issues |
|
|
|||
---|---|---|---|---|
|
No informatoion available | |||
|
- | |||
|
Not listed (Not listed) | |||
|
- | |||
|
- | |||
|
- |
|
![]() |
|
|
||
---|---|---|---|
|
ibafloxacin | ||
|
ibafloxacine | ||
|
- | ||
|
- | ||
|
- | ||
|
ibafloxacino | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 15/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |